C4 Therapeutics (CCCC) stock jumped 5% pre-market after expanding a partnership with Roche to develop cancer treatments. The collaboration targets degrader-antibody conjugates, with C4 receiving a $20 million upfront payment. The deal offers potential milestone payments exceeding $1 billion plus royalties, boosting the company's financial outlook for its oncology research programs.